Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in ...
Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, ...
Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is ...
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety ...
A research team at Lund University in Sweden has discovered a mechanism that helps acute myeloid leukemia cells to evade the body's immune system. By developing an antibody that blocks the mechanism, ...
Acute myeloid leukaemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in ...
Cancer cells are relentless in their quest to grow and divide, often rewiring their metabolism and modifying RNA to stay one step ahead. Now, researchers at the UCLA Health Jonsson Comprehensive ...
Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of immature myeloid cells. Its diversity stems from numerous genetic ...
At Liv Hospital, specialists emphasize that stem cell therapy isn’t a one-size-fits-all solution. Instead, it is carefully indicated for specific diseases, patient profiles, and treatment ...
Leukemic ocular involvement arises from direct infiltration, hematologic derangements (anemia, thrombocytopenia, hyperviscosity), opportunistic infections, or drug toxicity, and may be the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results